Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus

NCT05846971 is registered in ClinicalTrials.gov with Capsulomics, Inc. as lead sponsor.

NCT NCT05846971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05846971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Lead sponsor
Capsulomics, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
January 26, 2021
Completion date
December 31, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

barrett esophagus, esophageal cancer